TRADEA METILFENIDATO Farmacocinética El efecto terapéutico que ofrece TREDA es de horas con una sola dosis diaria. La ingesta de. Psicoestimulantes (metilfenidato e anfetaminas) são considerados como e hiperatividade; eficácia; dimesilato de anfetamina; farmacocinética; segurança. Metilfenidato. MET 3 mg/kg ip. ATX 1 mg/kg ip. -1 nicotina/ diresgulazione emotiva. Metilfenidato . Farmacocinetica per ATX. • Atomoxetine. EM 3,6/PM 21h.
|Published (Last):||6 September 2012|
|PDF File Size:||15.56 Mb|
|ePub File Size:||13.66 Mb|
|Price:||Free* [*Free Regsitration Required]|
The pharmacologically active fraction, d -amphetamine, is gradually released by hydrolysis of the LDX prodrug. To perform a systematic review of the literature of the efficacy and safety of LDX in the treatment of ADHD in children and adolescents.
Additional references were identified using references listed in those articles. Further data on LDX were requested from its manufacturer. The literature also reports efficacy in long-term treatment, with safety and tolerability profiles comparable to those of other stimulants used for the treatment of ADHD. Most of the adverse events associated with LDX are considered to be mild or moderate in severity, with the most common being loss of appetite and insomnia. ADHD has been described in various cultures and societies as the most common neurobehavioral disorder in children 1and is associated with poor performance in family, social and academic contexts, especially when not diagnosed and treated effectively 2 – 5.
Metilfenidato – Wikipedia
The most widely documented negative effects of ADHD include poor school performance in children and adolescents. The prevalence of ADHD worldwide in children under 18 years old is estimated at 5.
ADHD often persists beyond adolescence into adulthood, although the presentation of symptoms differs between adults, children, and adolescents Despite the extensive scientific literature and dozens of associations formed by people with ADHD and family members throughout the world, there are still substantial misconceptions about the nature of ADHD and its treatment. In a survey conducted in Brazil of representative groups of physicians, psychologists, teachers and the general public, each of these groups reported beliefs that were not based on scientific evidence Treatment strategies for ADHD include counseling, psychoeducation, psychotherapy, and pharmacological treatment.
Behavioral parent training, farmaocinetica management in the farmacociinetica and behavior interventions in various contexts are considered to be effective in managing ADHD Pharmacological therapy is an important part of management of ADHD, with psychostimulants considered first line metilfenodato Psychostimulants are considered the most metilfenirato of all the medications used to treat ADHD 16and are available in immediate- and prolonged-release formulations.
Potential limitations of the use of immediate-release formulations include the need for frequent doses that potentially reduce adherence, and fluctuations in serum levels which have been associated with adverse events.
Although there is some evidence for this, it is not yet clear whether immediate-release psychostimulants produce greater abuse potential than prolonged-release formulations Among the prolonged action psychostimulants used metilfenicato treating ADHD, there are various formulations of methylphenidate and amphetamine with differing means of release and half-lives. A recent Cochrane review demonstrated the efficacy of amphetamines in treating this disorder Lisdexamfetamine dimesylate LDX is the newest drug in this class, having been developed as a prodrug of dextroamphetamine d -amphetamine aimed at providing long-acting treatment effects and a reduced risk of abuse metklfenidato The purpose of this article is to review the pharmacokinetics, efficacy and safety of LDX in treating ADHD in children and adolescents.
Additional references were identified using the reference lists of those articles. They were sorted by topics, as indicated below. LDX is administered orally as metilfenifato inactive parent compound that is rapidly and almost completely absorbed in the gastrointestinal tract. LDX is subsequently metabolized by enzyme hydrolysis into l-lysine an essential amino acid and d -amphetamine, the active component 1720 Figure 1.
The hydrolysis of the inactive component to the active drug is a relatively slow process that occurs mainly in the blood 19 – In children years of age, the time to maximum blood concentration T max of d farmacpcinetica after the administration of a single dose of LDX 30, 50 or 70 mg was 3.
These parameters are similar to those of the immediate-release formulations of mixed-salt psychostimulants, but shorter than the T max of prolonged-release formulations such as Adderall XR Shire U. Furthermore, in another study that measured C maxT max and AUC in children years of age with ADHD, the interpatient variability as measured by the coefficient of variation for these parameters was lower for d -amphetamine following administration of a 70 mg dose of LDX than following the administration of 30 mg of extended-release mixed amphetamine salts This suggests that the concentrations of the active metabolite are proportional to the dose of LDX, with low variation among individuals 21 Some controlled-release formulations of psychostimulants are sensitive to alterations in gastric pH e.
Significant variations in the plasma levels of d -amphetamines were reported when one compared their administration with and without food intake Adderall XR 26 Given that LDX is a prodrug and not dependent on a controlled-release mechanism, the changes in gastrointestinal transit should not alter its effects Furthermore, food does not significantly or clinically affect the bioavailability of LDX The administration of a single dose of LDX after a high-fat meal compared with a fasting state resulted in a delay of approximately 1 hour in d -amphetamine T maxalthough the C max and AUC were similar LDX has demonstrable efficacy 2 hours after administration that is maintained up to 12 hours Another study reported beneficial effects of LDX lasting from 1.
In a 4-week, double-blind, randomized study in children, the evening rebound associated with LDX proved to be less than with placebo 2. Such aspects are potentially relevant for clinical practice due to the need for symptomatic control during various activities throughout the day In addition, the consistent plasma concentrations of the drug prevented fluctuations and the associated rebound effects.
In a study of potential abuse of LDX comparing intranasal administration with oral administration, similar values were found for C maxT maxAUC and half-life in both groups, indicating that intranasal dosing does not cause accelerated absorption LDX has been approved in the U. The first Phase II, randomized, cross-over study, with controls placebo and active controlcompared LDX 30, 50 or 70 mg with placebo in 52 school-age children in a laboratory classroom setting Extended-release mixed amphetamine salts 10, 20 or 30 mg were included as a reference arm during the study.
Patients years of age were initially treated with amphetamine salts for 3 weeks, followed by a double-blind crossover period during which they were given LDX, mixed amphetamine salts and placebo for 1 week each in a randomized order.
The second study was a Phase III, multi-center, placebo-controlled, forced-dose study in children who received LDX 30, 50 or 70 mg In a laboratory classroom study in school-children, LDX provided therapeutic efficacy in as little as 1.
TRADEA METILFENIDATO by chayo pineda on Prezi
The long-term efficacy of LDX was demonstrated in an month open-label study involving children Following dose-titration over the first 4 weeks, children years of age were given 30, 50 or 70 mg doses of LDX per day for a maintenance period of 11 months.
In addition, differences in total scores for all LDX doses were significant at all weeks of the study compared with metikfenidato. At the end of the study, One of the key aspects of the treatment of ADHD is the need to control symptoms at different times during the day, something that could be problematic when using short-acting formulations.
This study was conducted in children and adolescents, comparing LDX in doses of 30, 50 or 70 mg and atomoxetine 0. LDX was associated with a significantly more rapid and robust treatment response than atomoxetine.
This finding appears to support a Cochrane review which demonstrated the efficacy of amphetamines in the treatment of ADHD in adults 18something demonstrated for LDX in recent studies in adults Studies of pharmacological treatments for ADHD frequently use quality of life QoL and functional impairment indicators, aspects that are related but not necessarily proportional to the cardinal symptoms of ADHD.
Since LDX is a prodrug of d -amphetamine, one expects a tolerability profile similar to that of other amphetamines 43 ; this aspect has been confirmed in the literature 2332 – A systematic review and meta-analysis evaluating the drug options for Metilfdnidato management concluded that there were no significant differences in the relative risk of adverse events between non-stimulants and short-acting or extended-release stimulants The tolerability and safety of LDX were investigated in a 4-week study including children The most common adverse events in children were loss of appetite, dizziness, dry mouth, irritability, insomnia, upper abdominal pain, nausea, vomiting and weight loss Table 1.
Of all treatment-emergent adverse events, Long-term use of amphetamines has been associated with a temporary delay in growth rates in pediatric patients, something that appears to be significantly associated with weight loss. When normalized for age and gender, compared with baseline, the mean change in percentile was Consistent with other psychostimulants, after treatment with LDX there was a slowing in growth rate measured by weight gain in comparison with children of the same age and gender The results from a non-controlled study of children years of age with ADHD receiving LDX for up to 15 months showed that LDX was associated with significant reductions in height and weight Compared with age-appropriate standards, children who were given LDX had reduced gains in height and weight The authors noted that more studies are required to determine the effect of LDX on final stature in adulthood and recommend that, as with other psychostimulants, weight and height should be monitored 2746and treatment discontinuation should be considered in children who show inadequate growth and weight gain.
Based on data for amphetamines in general, cardiovascular risk associated with the use of LDX is believed to be low and changes in blood pressure BP and heart rate HR are considered to be small and not clinically significant However, LDX treatment was associated with significant increases in heart rate relative to placebo, with the largest increase bpm observed with the highest dose of LDX 70 mg There was, however, a significant increase in heart rate and pulse for LDX 2.
The use of amphetamines may be associated with changes in ECG parameters, although those changes have not been shown to be of clinical significance There was previous concern about cardiovascular risk associated with the use of methylphenidate and amphetamines in the treatment of ADHD in children 49but evidence indicates that cardiovascular events are rare and frequently associated with a pre-existing pathology and there is no increase in the risk of sudden death 45 The frequency of sudden death with the use of stimulants has been estimated to be around 0.
Despite there being no reports of cases of sudden death associated with the use of LDX in the literature, the probability of sudden death occurring must be considered to be similar to that of other psychostimulant medications Psychostimulants as a group have a potential for abuse which must be taken into consideration by the physician.
There have been reports of non-medical use by healthy individuals to increase cognitive performance and, in particular, academic performance 52 – One possible advantage of LDX is the absence of clinically significant psychoactive effects when administered by intranasal or intravenous means, in addition to the absence of an accelerated effect in terms of C max or T max when used by intranasal means 32potentially reducing the probability of abuse and misuse The abuse potential of LDX is considered to be less than that of d -amphetamine.
The results indicated that after 50 mg doses of LDX and 20 mg doses of d -amphetamine administered intravenously, only d -amphetamine differed significantly from the placebo in drug-craving ratings In a placebo-controlled study, orally-administered LDX 50, and mg was compared with d -amphetamine 40 mg equivalent to mg of LDX in adults years of age with a history of stimulant abuse There are no studies available on the abuse potential of LDX compared with other controlled-release stimulants used in the treatment of ADHD, and there are as yet no data available for populations other than adults.
LDX is an inactive prodrug that is metabolized to the active fraction d -amphetamine through rate-limited hydrolysis, resulting in the steady release of d -amphetamine and a prolonged effect following a single daily dose. In controlled clinical studies, LDX proved to be effective for the treatment fwrmacocinetica ADHD in children and adolescents, with results comparable to those of other available psychostimulants.
The therapeutic effects of LDX are achieved less than 1. In addition, LDX is effective in long-term maintenance therapy. The safety and tolerability profile of LDX is similar to that observed with other psychostimulants.
The pharmacokinetic profile of LDX is associated with a lower abuse potential than immediate-release psychostimulants. Social impairment in girls with ADHD: The effect of ADHD on the life of an individual, their family, and community from preschool to adult life.
Fletcher J, Wolfe B.
Long-term consequences of childhood ADHD on criminal activities. J Ment Health Policy Econ.
Academic performance in ADHD when controlled for comorbid learning disorders, family income, and parental education in Brazil. The worldwide prevalence of ADHD: ADHD in a school sample of Brazilian adolescents: ADHD in a representative sample of the Brazilian population: Int J Methods Psychiatr Res.
Early determinants of attention and hyperactivity problems in adolescents: